Search

Your search keyword '"Vittecoq D"' showing total 96 results
Start Over Author "Vittecoq D" Search Limiters Peer Reviewed
96 results on '"Vittecoq D"'

3. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus‐co‐infected patients (ANRS CO13‐HEPAVIH)

Author

Nordmann, S., Vilotitch, A., Roux, P., Esterle, L., Spire, B., Marcellin, F., Salmon‐Ceron, D., Dabis, F., Chas, J., Rey, D., Wittkop, L., Sogni, P., Carrieri, P., Salmon, D, Trimoulet, P, Izopet, J, Serfaty, L, Paradis, V, Valantin, M.A., Pialoux, G, Poizot‐Martin, I, Barange, K, Naqvi, A, Rosenthal, E, Bicart‐See, A, Bouchaud, O, Gervais, A, Lascoux‐Combe, C, Goujard, C, Lacombe, K, Duvivier, C, Vittecoq, D, Neau, D, Morlat, P, Bani‐Sadr, F, Meyer, L, Boufassa, F, Dominguez, S, Autran, B, Roque, A.M., Solas, C, Fontaine, H, Costagliola, D, Piroth, L, Simon, A, Zucman, D, Boué, F, Miailhes, P, Billaud, E, Aumaître, H, Couffin‐Cadiergues, S, Marchand, L, Salmon, D, Alagna, L, Sogni, P, Terris, B, Krivine, A, Katlama, C, Valantin, M.A., Stitou, H, Benhamou, Y, Charlotte, F, Fourati, S, Simon, A, Cacoub, P, Nafissa, S, Poizot‐Martin, I, Zaegel, O, Porcher, M, Tamalet, C, Pialoux, G, Chas, J, Slama, L, Callard, P, Bendjaballah, F, Le Pendeven, C, Marchou, B, Alric, L, Barange, K, Metivier, S, Selves, J, Larroquette, F, Rosenthal, E, Haudebourg, J, Saint‐Paul, M.C., Partouche, C, Bouchaud, O, Ziol, M, Baazia, Y, Uzan, M, Bicart‐See, A, Garipuy, D, Ferro‐Collados, M.J, Selves, J, Nicot, F, Gervais, A, Yazdanpanah, Y, Adle‐Biassette, H, Alexandre, G, Lascoux‐Combe, C, Molina, J.M, Bertheau, P, Duclos, J, Palmer, P, Lacombe, K, Campa, P, Girard, P.M, Wendum, D, Cervera, P, Adam, J, Viala, C, Goujard, C, Pallier, C, Vittecoq, D, Lortholary, O, Duvivier, C, Shoai‐Tehrani, M, Mélard, A, Neau, D, Ochoa, A, Blanchard, E, Castet‐Lafarie, S, Cazanave, C, Malvy, D, Dupon, M, Dutronc, H, Dauchy, F, Lacaze‐Buzy, L, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Morlat, P, Lacoste, D, Bonnet, F, Bernard, N, Bonarek Hessamfar, M, Roger‐Schmeltz, J, Gellie, P, Thibaut, P, Paccalin, F, Martell, C, Carmen Pertusa, M, Vandenhende, M, Mercier, P, Malvy, D, Pistone, T, Receveur, M.C, Caldato, S, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Pellegrin, J.L, Viallard, J.F, Lazzaro, E, Greib, C, Bioulac‐Sage, P, Trimoulet, P, Reigadas, S, Zucman, D, Majerholc, C, Guitard, F, Boué, F, Polo Devoto, J, Kansau, I, Chambrin, V, Pignon, C, Berroukeche, L, Fior, R, Martinez, V, Deback, C, Lévy, Y, Dominguez, S, Lelièvre, J.D, Lascaux, A.S, Melica, G, Billaud, E, Raffi, F, Alavena, C, Rodallec, A, Miailhes, P, Peyramond, D, Chidiac, C, Ader, F, Biron, F, Boibieux, A, Cotte, L, Ferry, T, Perpoint, T, Koffi, J, Zoulim, F, Bailly, F, Lack, P, Maynard, M, Radenne, S, Amiri, M, Le‐Thi, T.T, Piroth, L, Chavanet, P, Duong Van Huyen, M, Buisson, M, Waldner‐Combernoux, A, Mahy, S, Binois, R, Simonet‐Lann, A.L, Croisier‐Bertin, D, Aumaître, H, Bani‐Sadr, F, Lambert, D, Nguen, Y, Rouger, C, Berger, J.L, Partrisiani, M, Gautner, P, Batard, M.L, Beniken, D, Lupin, C, Lions, C, Ritleng, A.‐S, Honoré, P, Payssan, V, Breau, S, Joulie, A, Mole, M, Bolliot, C, Touam, F, André, F, Hue, H, Larmet, L, Brochier, C, Thoirain, V, Raho‐Moussa, M, Ogoudjobi, S, Azar, M, Bornarel, D, Gohier, S, Chesnel, C, Maradan, G, Kurkdji, P, Hadjoudj, S, Malet, M, Kmiec, I, Fischer, P, Palacin, A, Pietri, M.P, Le Baut, V, Guet, P, Le Puil, S, Mebarki, M, Fior, A, Adda‐Lievin, A, Conte, V, Delaune, J, Dequae Merchadou, L, Douiri, N, Gillet, S, Gilbert, C, Jacquet, A, Kherraz, R, Lagorse, P, Mora, M, Protopopescu, C, and Rosellini, S

Published
2018
Full Text
View/download PDF

6. Levels and determinants of breast and cervical cancer screening uptake in HIV‐infected women compared with the general population in France

Author

Tron, L, Lert, F, Spire, B, DraySpira, R, Allègre, T, Mours, P., Riou, J.M., Sordage, M., Chennebault, J. M., Fialaire, P., Rabier, V., Froidure, M., Huguet, D., Leduc, D., Pichancourt, G., Wajsbrot, A., Bourdeaux, C., Foltzer, A., Hoen, B., HustacheMathieu, L., Abgrall, S., Barruet, R., Bouchaud, O., Chabrol, A., Mattioni, S, Mechai, F., Jeantils, V., Bernard, N., Bonnet, F., Hessamfar, M., Lacoste, D., Malvy, D., Mercié, P., Morlat, P., Paccalin, F., Pertusa, M. C., Pistone, T., Receveur, M. C., Vandenhende, M. A., Dupont, C., Freire Maresca, A., Leporrier, J., Rouveix, E., Dargere, S., de la Blanchardière, ., Martin, A., Noyon, V., Verdon, R., Rogeaux, O., Beytout, J., Gourdon, F., Laurichesse, H., Meier, F., Mortier, E., Simonpoli, A. M., Cordier, F., Delacroix, I., Garrait, V., Elharrar, B., Dominguez, S., Lascaux, A. S., Lelièvre, J. D., Levy, Y., Melica, G., Buisson, M., Piroth, L., Waldner, A., Gruat, N., Leprêtre, A., de Truchis, P., Le Du, D, Melchior, J. Cl., Sehouane, R., Troisvallets, D., Blanc, M., BocconGibod, I., Bosseray, A., Brion, J. P., Durand, F., Leclercq, P., Marion, F., Pavese, P., BrottierMancini, E., Faba, L., RoncatoSaberan, M., BollengierStragier, O., Esnault, J. L., LeautezNainville, S., Perré, P., Froguel, E., Nguessan, M., Simon, P., Colardelle, P., Doll, J., GodinCollet, C., RoussinBretagne, S., Delfraissy, J. F., Duracinsky, M., Goujard, C., Peretti, D., Quertainmont, Y., Marionneau, J., Aissi, E., Van Grunderbeeck, N, Denes, E., DucroixRoubertou, S., Genet, C., Weinbreck, P., AugustinNormand, C., Boibieux, A., Cotte, L., Ferry, T., Koffi, J., Miailhes, P., Perpoint, T., Peyramond, D., Schlienger, I., Brunel, J. M., Carbonnel, E., Chiarello, P., Livrozet, J. M., Makhloufi, D., Dhiver, C., Husson, H., Madrid, A., Ravaux, I., de Severac, M.L., Thierry Mieg, M., Tomei, C., Hakoun, S., Moreau, J., Mokhtari, S., Soavi, M. J., Faucher, O., Ménard, A., Orticoni, M., PoizotMartin, I., Soavi, M. J., Atoui, N., Baillat, V., Faucherre, V., Favier, C., Jacquet, J. M., Le Moing, V, Makinson, A., Mansouri, R., Merle, C., Elforzli, N., Allavena, C., Aubry, O., Besnier, M., Billaud, E., Bonnet, B., Bouchez, S., Boutoille, D., Brunet, C., Feuillebois, N., Lefebvre, M., MorineauLe Houssine, P, Mounoury, O., Point, P., Raffi, F., Reliquet, V., Talarmin, J. P., Ceppi, C., Cua, E., Dellamonica, P., De SalvadorGuillouet, Durant, J., Ferrando, S., MondainMiton, V., Perbost, I., Pillet, S., ProuvostKeller, B., Pradier, C., Pugliese, P., Roger, P. M., Rosenthal, E., Sanderson, F., Hocqueloux, L., Niang, M., Prazuck, T., Arsac, P., BarraultAnstett, M.F., Ahouanto, M., Bouvet, E., Castanedo, G., CharloisOu, C., Dia Kotuba, A., EidAntoun, Z., Jestin, C., Jidar, K., Joly, V., KhuongJosses, M. A., Landgraf, N., Landman, R., Lariven, S., Leprêtre, A., Lʼhériteau, F., Machado, M., Matheron, S., Michard, F., Morau, G., Pahlavan, G., Phung, B. C., Prévot, M. H., Rioux, C., Yéni, P., BaniSadr, F., Calboreanu, A., Chakvetadze, E., Salmon, D., Silbermann, B., Batisse, D., Beumont, M., Buisson, M., Castiel, P., Derouineau, J., Eliaszewicz, M., Gonzalez, G., Jayle, D., Karmochkine, M., Kousignian, P., Pavie, J., Pierre, I., Weiss, L., Badsi, E., Bendenoun, M., Cervoni, J., Diemer, M., Durel, A., Rami, A., Sellier, P., AitMohand, H., Amirat, N., Bonmarchand, M., Bourdillon, F., Breton, G., Caby, F., Grivois, J. P., Katlama, C., Kirstetter, M., Paris, L., Pichon, F., Roudière, L., Schneider, L., Samba, M. C., Seang, S., Simon, A., Stitou, H., Tubiana, R., Valantin, M. A., Bollens, D., Bottero, J., Bui, E., Campa, P., Fonquernie, L., Fournier, S., Girard, P. M., Goetschel, A., Guyon, H. F., Lacombe, K., Lallemand, F., Lefebvre, B., Maynard, J. L., Meyohas, M. C., Ouazene, Z., Pacanowski, J., Picard, O., Raguin, G., Roussard, P., Tourneur, M., Tredup, J., Valin, N., Balkan, S., Clavel, F., Colin de Verdière, N, De Castro, N., de Lastours, V., Ferret, S., Gallien, S., Garrait, V., Gérard, L., Goguel, J., Lafaurie, M., LascouxCombe, C., Molina, J. M., Oksenhendler, E., Pavie, J., Pintado, C., Ponscarme, D., Rozenbaum, W., Scemla, A., Bonnard, P., Lassel, L., Lebrette, M. G., Lyavanc, T., Mariot, P., Missonnier, R., Ohayon, M., Pialoux, G., Treilhou, M. P., Vincensini, J. P., Gilquin, J., Hadacek, B., NaitIghil, L., Nguyen, T. H., Pintado, C., Sobel, A., Viard, J. P., Zak Dit Zbar, O., Aumaître, H., Eden, A., Ferreyra, M., Lopez, F., Medus, M., Neuville, S., Saada, M., Blum, L., Perfezou, P., Arvieux, C., Chapplain, J. M., Revest, M., Souala, F., Tattevin, P., Bord, S., BorsaLebas, F., Caron, F., Chapuzet, C., Debab, Y., Gueit, I., Etienne, M., Fartoukh, C., Feltgen, K., Joly, C., RobadayVoisin, S., Suel, P., Khuong, M. A., Krausse, J., Poupard, M., Tran Van, G., Cazorla, C., Daoud, F., Fascia, P., Frésard, A., Guglielminotti, C., Lucht, F., BernardHenry, C., Cheneau, C., Lang, J. M., de Mautort, E., Partisani, M., Priester, M., Rey, D., Majerholc, C., Zucman, D., Assi, A., Lafeuillade, A., de Jaureguiberry, J. P., Gisserot, O., Aquilina, C., Prevoteau du Clary, F., Alvarez, M., Chauveau, M., Cuzin, L., Delobel, P., Garipuy, D., Labau, E., Marchou, B., Massip, P., Mularczyk, M., Obadia, M., Ajana, F., Allienne, C., Baclet, V., de la Tribonnière, X, Huleux, T., Melliez, H., Meybeck, A., Riff, B., Valette, M., Viget, N., Bastides, F., Bernard, L., Gras, G., Guadagnin, P., May, T., Rabaud, C., Dos Santos, A, P oinsignon, Y., Derradji, O., Escaut, L., Teicher, E., Vittecoq, D., Bantsima, J., CarauxPaz, P., and Patey, O.

Published
2017
Full Text
View/download PDF

10. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies

Author

Frange, Pierre, Assoumou, Lambert, Descamps, Diane, Chéret, Antoine, Goujard, Cécile, Tran, Laurent, Gousset, Marine, Avettand-Fenoël, Veronique, Bocket, Laurence, Fafi-Kremer, Samira, Guinard, Jerome, Morand-Joubert, Laurence, Nicot, Florence, Plantier, Jean-Christophe, Rogez, Sylvie, Wirden, Marc, Rouzioux, Christine, Meyer, Laurence, Chaix, Marie-Laure, Abel, S., Abraham, B., Allegre, T., Antoniotti, A., Armero, R., Audhuy, B., Aumaitre, H., Beaucaire, G., Beck-Wirth, G., Berger, J.L., Bernard, L., Beuscart, C., Bodard, L., Bouchaud, O., Boué, F., Cabane, J.-P., Cabie, A., Champagne, H., Cheneau, C., Chennebault, J.-M., Cheret, A., Christian, B., Compagnucci, A., Daneluzzi, V., Debab, Y., Dellamonica, P., Delfraissy, J.-F., Devidas, A., Diab, G., Doll, J., Drobacheff-Thebaut, M.C., Durel, A., Duvivier, C., Esnault, J.-L., Faba, L., Froguel, E., Garipuy, D., Garrait, V., Geffray, L., Genet, C., Genet, P., Gerard, L., Ghosn, J., Girard, J-.J., Girard, P.-M., Godin-Collet, C., Hochedez, P., Hoen, B., Houlbert, D., Jacomet, C., Jeantils, V., Jidar, K., Katlama, C., Klement, E., Lafeuillade, A., Lascoux, C., Launay, V., Lepretre, A., Levy, Y., Makhloufi, D., Malbec, D., Martha, B., May, T., Merrien, D., Miailhes, P., Miodovski, C., Molina, J.-M., Morlat, P., Mortier, E., Neau, D., Obadia, M., Patey, O., Pellegrin, J.-L., Perronne, V., Philibert, P., Pialoux, G., Pichancourt, G., Piroth, L., Poinsignon, Y., Poizot-Martin, I., Prazuck, T., Prendki, V., du Clary, F. Preveteau, Quinsat, D., Raffi, F., Regnier, A., Reynes, J., Rosenthal, E., Rouveix, E., Salmon, D., Salanville, F., Schmitt, J.-L., Simon-Coutellier, A., Sotto, A., Souala, F., Stein, A., Timsit, F., de Truchis, P., Uludag, A., Vaillant, O., Verdon, R., Verlesch-Langlin, A., Viard, J.-P., Vittecoq, D., Weiss, L., Yéni, P., Zucman, D., Allavena, C., Allegre, T., Amri, I., Autran, B., Bacchus, C., Blanc, C., Bonne, S., Bonnet, B., Bouchez, S., Charlier, C., Consigny, P.-H., Duvivier, C., Fourn, E., Guiroy, F., Huleux, T., Katlama, C., Lascoux-Combe, C., Leplatois, A., Lyavanc, T., Molina, J.-M., Naqvi, A., Nembot, G., Quertainmont, Y., Raffi, F., Samri, A., Schneider, L., Seang, S., Seksik, B.C.P., Shoai-Tehrani, M., Slama, L., Valentin, M.-A., Yazdanpanah, Y., Alloui, C., Amiel, C., André, P., André-Garnier, E., Anies, G., Barin, F., Bellecave, P., Bettinger, D., Bouvier-Alias, M., Brun-Vézinet, F., Calmy, A., Calvez, V., Caveng, W., Chaillon, A., Chapalay, S., Charpentier, C., Costagliola, D., Cottalorda, J., Delamare, C., Delaugerre, C., Dina, J., Santos, G. Dos, Férré, V., Flandre, P., Fleury, H., Fourati, S., Gaille, C., Giraudeau, G., Guigon, A., Haim-Boukobza, S., Lagier, E., Le Guillou-Guillemette, H., Henquell, C., Izopet, J., Lambert-Niclot, S., Leroux, M., Maillard, A., Malet, I., Marcelin, A.-G., Marque-Juillet, S., Masquelier, B., Mirand, A., Morand, P., Montes, B., Mouna, L., Noel, C., Pallier, C., Peytavin, G., Pinson-Recordon, P., Poveda, J.D., Raymond, S., Reigadas, S., Roques, A.-M., de Rougemont, A., Roussel, C., Schmitt, M.-P., Schneider, V., Schvoerer, E., Signori-Schmuck, A., Soulié, C., Tamalet, C., Tardy, J.C., Trabaud, M.-A., Vabret, A., Vallet, S., and Yerly, S.

Published
2015
Full Text
View/download PDF

11. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

Author

Fourati, Slim, Charpentier, Charlotte, Amiel, Corinne, Morand-Joubert, Laurence, Reigadas, Sandrine, Trabaud, Mary-Anne, Delaugerre, Constance, Nicot, Florence, Rodallec, Audrey, Maillard, Anne, Mirand, Audrey, Jeulin, Hélène, Montès, Brigitte, Barin, Francis, Bettinger, Dominique, Le Guillou-Guillemette, Hélène, Vallet, Sophie, Signori-Schmuck, Anne, Descamps, Diane, Calvez, Vincent, Flandre, Philippe, Marcelin, Anne-Genevieve, Lagier, E., Roussel, C., Le Guillou, H., Alloui, C., Bettinger, D., Pallier, C., Fleury, H., Reigadas, S., Bellecave, P., Recordon-Pinson, P., Payan, C., Vallet, S., Vabret, A., Henquell, C., Mirand, A., Bouvier-Alias, M., de Rougemont, A., Dos Santos, G., Morand, P., Signori-Schmuck, A., Bocket, L., Rogez, S., Andre, P., Tardy, J. C., Trabaud, M. A., Tamalet, C., Delamare, C., Montes, B., Schvoerer, E., Ferre, V., André-Garnier, E., Cottalorda, J., Guinard, J., Guiguon, A., Descamps, D., Brun-Vézinet, F., Charpentier, C., Visseaux, B., Peytavin, G., Krivine, A., Si-Mohamed, A., Avettand-Fenoel, V., Marcelin, A. G., Calvez, V., Lambert-Niclot, S., Soulié, C., Wirden, M., Morand-Joubert, L., Delaugerre, C., Chaix, M. L., Amiel, C., Schneider, V., Giraudeau, G., Brodard, V., Maillard, A., Plantier, J. C., Chaplain, C., Bourlet, T., Fafi-Kremer, S., Stoll-Keller, F., Schmitt, M. P., Barth, H., Yerly, S., Poggi, C., Izopet, J., Raymond, S., Barin, F., Chaillon, A., Marque-Juillet, S., Roque-Afonso, A. M., Haïm-Boukobza, S., Flandre, P., Grudé, M., Assoumou, L., Costagliola, D., Allegre, T., Schmit, J. L., Chennebault, J. M., Bouchaud, O., Magy-Bertrand, N., Delfraissy, J. F., Dupon, M., Morlat, P., Neau, D., Ansart, S., Jaffuel, S., Verdon, R., Jacomet, C., Lévy, Y., Dominguez, S., Chavanet, P., Piroth, L., Cabié, A., Leclercq, P., Ajana, F., Cheret, A., Weinbreck, P., Cotte, L., Poizot-Martin, I., Ravaud, I., Christian, B., Truchetet, F., Grandidier, M., Reynes, J., May, T., Goehringer, F., Raffi, F., Dellamonica, P., Prazuck, T., Hocqueloux, L., Yéni, P., Landman, R., Launay, O., Weiss, L., Viard, J. P., Katlama, C., Simon, A., Girard, P.M., Meynard, J. L., Molina, J. M., Pialoux, G., Hoen, B., Goeger-Sow, M. T., Lamaury, I., Beaucaire, G., Jaussaud, R., Rouger, C., Michelet, C., Borsa-Lebas, F., Caron, F., Khuong, M. A., Lucht, F., Rey, D., Calmy, A., Marchou, B., Gras, G., Greder-Belan, A., Vittecoq, D., and Teicher, E.

Published
2015
Full Text
View/download PDF

21. Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial

Author

Charpentier, Charlotte, Joly, Véronique, Larrouy, Lucile, Fagard, Catherine, Visseaux, Benoit, de Verdière, Nathalie Colin, Raffi, François, Yeni, Patrick, Descamps, Diane, Aumaître, H., Medus, M., Neuville, S., Saada, M., Abgrall, S., Bentata, M., Bouchaud, O., Cailhol, J., Cordel, H., Dhote, R., Gros, H., Honoré-Berlureau, P., Huynh, T., Krivitzky, A., Mansouri, R., Poupard, M., Prendki, V., Radia, D., Rouges, F., Touam, F., Warde, B., de Castro, N., Colin de Verdière, N., Delgado, J., Ferret, S., Gallien, S., Kandel, T., Lafaurie, M., Lagrange, M., Lascoux-Combe, C., Le, D., Molina, J. M., Pavie, J., Pintado, C., Ponscarme, D., Rachline, A., Rozenbaum, W., Sereni, D., Taulera, O., Estavoyer, J. M., Faucher, J. F., Foltzer, A., Hoen, B., Hustache-Mathieu, L., Dupon, M., Dutronc, H., Neau, D., Ragnaud, J. M., Raymond, I., Boucly, S., Lortholary, O., Viard, J. P., Bechara, C., Delfraissy, J. F., Ghosn, J., Goujard, C., Kamouh, W., Môle, M., Quertainmont, Y., Bergmann, J. F., Boulanger, E., Castillo, H., Parrinello, M., Rami, A., Sellier, P., Lepeu, G., Pichancourt, G., Bernard, L., Berthé, H., Clarissou, J., Gory, M., Melchior, J. C., Perronne, C., Stegman, S., de Truchis, P., Derradji, O., Malet, M., Teicher, E., Vittecoq, D., Chakvetadze, C., Fontaine, C., Lukiana, T., Pialloux, G., Slama, L., Bonnet, D., Boucherit, S., El Alami Talbi, N., Fournier, I., Gervais, A., Joly, V., Iordache, L., Laurichesse, J. J., Leport, C., Pahlavan, G., Phung, B. C., Yeni, P., Bennamar, N., Brunet, A., Guillevin, L., Salmon-Ceron, D., Tahi, T., Chesnel, C., Dominguez, S., Jouve, P., Lelièvre, J. D., Levy, Y., Melica, G., Sobel, A., Ben Abdallah, S., Bonmarchand, M., Bricaire, F., Herson, S., Iguertsira, M., Katlama, C., Kouadio, H., Schneider, L., Simon, A., Valantin, M. A., Abel, S., Beaujolais, V., Cabié, A., Liauthaud, B., Pierre François, S., Abgueguen, P., Chennebault, J. M., Loison, J., Pichard, E., Rabier, V., Delaune, J., Louis, I., Morlat, P., Pertusa, M. C., Brunel-Delmas, F., Chiarello, P., Jeanblanc, F., Jourdain, J. J., Livrozet, J. M., Makhloufi, D., Touraine, J. L., Augustin-Normand, C., Bailly, F., Benmakhlouf, N., Brochier, C., Cotte, L., Gueripel, V., Koffi, K., Lack, P., Lebouché, B., Maynard, M., Miailhes, P., Radenne, S., Schlienger, I., Thoirain, V., Trepo, C., Drogoul, M. P., Fabre, G., Faucher, O., Frixon-Marin, V., Gastaut, J. A., Peyrouse, E., Poizot-Martin, I., Jacquet, J. M., Le Facher, G., Merle de Boever, C., Reynes, J., Tramoni, C., Allavena, C., Billaud, E., Biron, C., Bonnet, B., Bouchez, S., Boutoille, D., Brunet-François, C., Hüe, H., Mounoury, O., Raffi, F., Reliquet, V., Aubry, O., Esnault, J. L., Leautez-Nainville, S., Perré, P., Suaud, I., Bréaud, S., Ceppi, C., Dellamonica, P., De Salvador, F., Durant, J., Ferrando, S., Fuzibet, J. G., Leplatois, A., Mondain, V., Perbost, I., Pugliese, P., Rahelinirina, V., Rosenthal, E., Sanderson, F., Vassalo, M., Arvieux, C., Chapplain, J. M., Michelet, C., Ratajczak, M., Revest, M., Souala, F., Tattevin, P., Chéneau, C., Fischer, P., Lang, J. M., Partisani, M., Rey, D., Bastides, F., Besnier, J. M., Le Bret, P., Choutet, P., Dailloux, J. F., Guadagnin, P., Nau, P., Rivalain, J., Soufflet, A., Aïssi, E., Melliez, H., Pavel, S., Mouton, Y., Yazdanpanah, Y., Boyer, L., Burty, C., Letranchant, L., May, T., Wassoumbou, S., Blum, L., Danne, O., Arthus, M. A., Dion, P., Certain, A., Tabuteau, S., Beuscart, A., Agher, N., Frosch, A., Couffin-Cadiergues, S., and Diallo, A.

Published
2013
Full Text
View/download PDF

22. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir

Author

Bommenel, T., Launay, O., Meynard, J. L., Gilquin, J., Katlama, C., Lascaux, A. S., Mahamat, A., Martinez, V., Pradier, C., Rouveix, E., Simon, A., Costagliola, D., Abgrall, S., Abgrall, S., Barin, F., Bentata, M., Billaud, E., Boué, F., Burty, C., Cabié, A., Costagliola, D., Cotte, L., de Truchis, P., Duval, X., Duvivier, C., Enel, P., Gasnault, J., Gaud, C., Gilquin, J., Grabar, S., Katlama, C., Khuong, M. A., Lang, J. M., Lascaux, A. S., Launay, O., Mahamat, A., Mary-Krause, M., Matheron, S., Meynard, J. L., Pavie, J., Pialoux, G., Pilorgé, F., Poizot-Martin, I., Pradier, C., Reynes, J., Rouveix, E., Simon, A., Tattevin, P., Tissot-Dupont, H., Viard, J. P., Viget, N., Brosseau, M., Salomon, V., Jacquemet, N., Guiguet, M., Lanoy, E., Lièvre, L., Selinger-Leneman, H., Lacombe, J. M., Potard, V., Bricaire, F., Herson, S., Desplanque, N., Girard, P. M., Meyohas, M. C., Picard, O., Cadranel, J., Mayaud, C., Clauvel, J. P., Decazes, J. M., Gerard, L., Molina, J. M., Diemer, M., Sellier, P., Honoré, P., Jeantils, V., Tassi, S., Mechali, D., Taverne, B., Bouvet, E., Crickx, B., Ecobichon, J. L., Picard-Dahan, C., Yeni, P., Berthé, H., Dupont, C., Chandemerle, C., Mortier, E., Tisne-Dessus, D., Weiss, L., Salmon, D., Auperin, I., Roudière, L., Fior, R., Delfraissy, J. F., Goujard, C., Jung, C., Lesprit, P., Vittecoq, D., Fraisse, P., Rey, D., Beck-Wirth, G., Stahl, J. P., Lecercq, P., Gourdon, F., Laurichesse, H., Fresard, A., Lucht, F., Bazin, C., Verdon, R., Chavanet, P., Arvieux, C., Michelet, C., Choutet, P., Goudeau, A., Maître, M. F., Hoen, B., Elinger, P., Faller, J. P., Borsa-Lebas, F., Caron, F., Daurès, J. P., May, T., Rabaud, C., Berger, J. L., Rémy, G., Arlet-Suau, E., Cuzin, L., Massip, P., Thiercelin Legrand, M. F., Pontonnier, G., Yasdanpanah, Y., Dellamonica, P., Pugliese, P., Aleksandrowicz, K., Quinsat, D., Ravaux, I., Delmont, J. P., Moreau, J., Gastaut, J. A., Retornaz, F., Soubeyrand, J., Galinier, A., Ruiz, J. M., Allegre, T., Blanc, P. A., Bonnet-Montchardon, D., Lepeu, G., Granet-Brunello, P., Esterni, J. P., Pelissier, L., Cohen-Valensi, R., Nezri, M., Chapadaud, S., Laffeuillade, A., Raffi, F., Boibieux, A., Peyramond, D., Livrozet, J. M., Touraine, J. L., Trepo, C., Strobel, M., Bissuel, F., Pradinaud, R., Sobesky, M., and Contant, M.

Published
2011
Full Text
View/download PDF

27. Clearance of carbapenem-resistant Enterobacteriaceae vs vancomycin-resistant enterococci carriage after faecal microbiota transplant: a prospective comparative study.

Author

Dinh, A., Fessi, H., Duran, C., Batista, R., Michelon, H., Bouchand, F., Lepeule, R., Vittecoq, D., Escaut, L., Sobhani, I., Lawrence, C., Chast, F., Ronco, P., and Davido, B.

Abstract

Background: Carbapenem-resistant Enterobacteriaceae (CRE) and vancomycin-resistant enterococci (VRE) carriage are increasing worldwide. Faecal microbiota transplantation (FMT) appears to be an attractive option for decolonization. This study aimed to evaluate CRE vs VRE clearance by FMT among carriers.Methods: A multi-centre trial was undertaken on patients with CRE or VRE digestive tract colonization who received FMT between January 2015 and April 2017. Adult patients with CRE or VRE colonization, confirmed by three consecutive rectal swabs at weekly intervals, including one in the week prior to FMT, were included in the study. Patients with immunosuppression or concomitant antibiotic prescription at the time of FMT were excluded. Successful decolonization was determined by at least two consecutive negative rectal swabs [polymerase chain reaction (PCR) and culture] on Days 7, 14, 21 and 28, and monthly for three months following FMT.Results: Seventeen patients were included, with a median age of 73 years [interquartile range (IQR) 64.3-79.0]. Median duration of carriage of CRE or VRE before FMT was 62.5 days (IQR 57.0-77.5). One week after FMT, three of eight patients were free of CRE colonization and three of nine patients were free of VRE colonization. After three months, four of eight patients were free of CRE colonization and seven of eight patients were free of VRE colonization. Qualitative PCR results were concordant with culture. Six patients received antibiotics during follow-up, three in each group. No adverse events were reported.Conclusion: CRE and VRE clearance rates were not significantly different in this study, possibly due to the small sample size, but a trend was observed. These data should be confirmed by larger cohorts and randomized trials. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

29. Is faecal microbiota transplantation an option to eradicate highly drug-resistant enteric bacteria carriage?

Author

Davido, B., Batista, R., Michelon, H., Lepainteur, M., Bouchand, F., Lepeule, R., Salomon, J., Vittecoq, D., Duran, C., Escaut, L., Sobhani, I., Paul, M., Lawrence, C., Perronne, C., Chast, F., and Dinh, A.

Abstract

Carbapenem-resistant Enterobacteriaceae (CRE) or vancomycin-resistant enterococci (VRE) carriage present a major public health challenge. Decolonization strategies are lacking. We aimed to evaluate the impact of faecal microbiota transplantation (FMT) on a cohort of patients with digestive tract colonization by CRE or VRE. Eight patients were included: six carrying CRE and two colonized by VRE. One month after FMT, two patients were free from CRE carriage, and another patient was free from VRE after three months. In our experience, this strategy is safe. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

34. Differential improvement in survival among patients with AIDS after the introduction of HAART.

Author

Couzigou, C., Semaille, C., Le Strat, Y., Pinget, R., Pillonel, J., Lot, F., Cazein, F., Vittecoq, D., Desenclos, J.-C., and The Aids Survival Study Group

Subjects
AIDS patients, ANTIRETROVIRAL agents, RISK assessment, HIV infection transmission
Abstract

We explored changes in the survival of patients with AIDS (PWA) according to the availability of antiretroviral drugs (1994-2002). We tested whether changes in the hazard ratio of progression to death (HR) have been homogeneous among various groups of PWA. We included 4158 PWA diagnosed in Paris, notified to the French National Surveillance Institute by 2002. Four calendar periods were defined: monotherapy (1994-95), bitherapy-HAART transition (1996), early HAART (1997-99), late HAART (2000-October 2002). HR were calculated with Cox models, including the calendar period, modelled as a time dependent covariate. Models were stratified by age, transmission category, CD4 cell count, and AIDS-defining illnesses (ADI) group. Cumulative survival at 60 months increased from 44.0% (before July 1996) to 75.6% (after July 1996) and median survival increased from 31.9 months to >76 months. Adjusted HR reached a minimum in the late HAART period (HR 0.22, 95% CI: 0.19-0.26). No difference in the decrease of the HR has been found by age. HR decreased and was marked during the late HAART period across all HIV transmission categories, including intravenous drug use. HR decreased significantly for all ADIs groups, including tumours. Among PWA diagnosed with tuberculosis, the HR decreased significantly only in the late HAART period. HR decrease was stronger for PWA with a CD4 cell count ≤200/mm3. Substantial improvements in survival after the introduction of HAART were found for all PWA but varied by specific ADIs and the degree of immunosuppression. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

35. Toxicité des antirétroviraux chez les patients co-infectés par les virus VIH et VHC.

Author

Roser, F., Soyer, A., Duclos-Vallée, J.-C., Teicher, E., Sebagh, M., Azoulay, D., Samuel, D., Vittecoq, D., and Lemoine, A.

Subjects
ANTIRETROVIRAL agents, HIV-positive persons, LIVER transplantation, HEPATITIS C virus, HIV infections
Abstract

Copyright of IBS, Immuno-analyse & Biologie Specialisee is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2006
Full Text
View/download PDF

37. Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo‐controlled trial in AIDS patients.

Author

Dubreuil‐Lemaire, M‐L., Gori, A., Vittecoq, D., Panelatti, G., Tharaux, F., Palisses, R., Gharakhanian, S., and Rozenbaum, W.

Subjects
GRANULOCYTE-colony stimulating factor, AIDS, CYTOMEGALOVIRUS diseases, NEUTROPHILS
Abstract

This phase IIa, randomised, single‐blind, placebo‐controlled study was conducted to determine the dose of recombinant human granulocyte colony‐stimulating factor (lenograstim) suitable for use in AIDS patients. The study was conducted at 27 European AIDS/HIV centres, and recruited 69 AIDS patients with an initial episode or relapse of cytomegalovirus infection (neurological site excluded) and an absolute neutrophil count (ANC) ≤1.0×109/L upon diagnosis or between days 1 and 12 of ganciclovir (GCV) treatment. The patients were randomised to placebo (n=14) or one of four lenograstim arms: 150 µg/m2/d (the standard onco‐haematology dose, n=13) or 100 (n=13), 50 (n=15), or 25 µg/m2/d (n=14). In all groups, the planned dose of GCV was 10mg/kg/d for 21 d. Median ANC at weeks 2 and 3 was significantly higher in each lenograstim group than in the placebo group (p=0.05). At week 3, median ANC (×109/L) was 0.7 in the placebo group, compared with 6.0, 7.4, 4.5, and 2.0 in the 150, 100, 50, and 25 µg2/d lenograstim groups, respectively. Median ANC was not significantly different between the 150, 100, and 50 µg/m2/d lenograstim groups at any time point, but significantly higher in the 50 than in the 25 µg/m2/d group at weeks 2 (p=0.05) and 3 (p=0.02). Lenograstim was generally well tolerated, leading to no severe adverse events. In conclusion, lenograstim 50µg/m2/d is suitable for the treatment of ganciclovir‐induced neutropenia and is safe. These results should help the physician choose an optimal and cost‐efficient regimen for patients with AIDS‐related neutropenia when rHuG‐CSF support is indicated. [ABSTRACT FROM AUTHOR]

Published
2000
Full Text
View/download PDF

38. Intestinal Absorption and Permeability in Human Immunodeficiency Virus-Infected Patients.

Author

Pernet, P., Vittecoq, D., Kodjo, A., Randrianarisolo, M.-H., Dumitrescu, L., Blondon, H., Bergmann, J.-F., Giboudeau, J., and Aussel, C.

Subjects
*HIV antibodies, *GASTROINTESTINAL system
Abstract

Background: Impaired intestinal function could account for diarrhoea and weight loss, which are common features of advanced human immunodeficiency virus (HIV) infection. Methods: We assessed intestinal permeability to lactulose and mannitol and absorption of D-xylose in 96 HIV-infected patients (group I: asymptomatic subjects (CDC-A); group II: symptomatic subjects (CDC-B or C) without body weight loss and/or diarrhoea; group III: 25 acquired immunodeficiency syndrome (AIDS) patients (CDC-C) with severe body weight loss and/or diarrhoea) and 10 healthy subjects as controls. Results: An incremental decrease in urinary D-xylose recoveries was observed, with all groups statistically different from each other. Impaired intestinal permeability was only found in patients of group III (statistically different from all other groups). Conclusions: These findings suggest a loss of intestinal functional absorptive surface as HIV disease progresses. This process may be present at the early stage of infection. Impaired intestinal permeability is observed later in AIDS patients when digestive signs are present, particularly diarrhoea. [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

39. Penetration of imipenem and cilastatin into cerebrospinal fluid of patients with bacterial meningitis.

Author

Modai, J., Vittecoq, D., Decazes, J. M., and Meulemans, A.

Abstract

The penetration of imipenem and cilastatin into the cerebrospinal fluid (CSF) was determined in patients with bacterial meningitis. Four 1000 mg/kg doses of both imipenem and cilastatin were infused intravenously over 20–30 min at 6 h intervals, first between days 2 and 4, and again, whenever possible, between days 11 to 20, in 12 patients with bacterial meningitis undergoing treatment with other antibiotics. Concentrations of imipenem and cilastatin in serum and cerebrospinal fluid samples obtained either at 60, 90 or 120 min following the fourth dose were measured by high pressure liquid chromatography. Concentrations of imipenem in CSF ranged from 0·5 to 11 mg/l and concentrations of cilastatin ranged from 1·1 to 10·5 mg/l, depending on the sampling time and the time elapsed since the onset of the disease. [ABSTRACT FROM PUBLISHER]

Published
1986

41. Prognosis of ruptured intracranial mycotic aneurysms: a review of 12 cases.

Author

MONSUEZ, J. J., VITTECOQ, D., ROSENBAUM, A., GOUJON, C., WOLFF, M., WITCHITZ, S., and MODAI, J.

Abstract

Intracranial mycotic aneurysms (IMA) occur in 1–3% of all infective endocarditis. Although spontaneous resolution was evidenced on serial angiograms in many asymptomatic cases, the prognosis, if they rupture, is reported to be worse and partly contingent on the therapeutic approach. Among 12 patients (six acute and six subacute endocarditis) with ruptured IMA, six were treated surgically and four were treated medically. Two patients died during rupture before any treatment could be started. Six patients had a sudden rupture manifested by coma (6), less clear consciousness (3), seizures (5), hemiparesis (8), unilateral mydriasis (3). CT-Scan showed intracerebral (8), intraventricular (3) and subarachnoid (2) haemorrhage. Ten angiograms showed 11 IMA. For patients with ruptured IMA, the decision for surgical treatment was made in the presence of deepening coma and extensive mass-lesion on CT-scan (one of six died in the postoperative period). Others received medical treatment (four cases: all survived) and were followed-up with serial angiographies. Of the nine patients who survived, five remained free of any disability 1-4 years later. We suggest that the prognosis of ruptured IMA (25% mortality rate) is not as bad as previously reported if surgery following angiography is performed early in the presence of deepening coma and extensive lesion. [ABSTRACT FROM PUBLISHER]

Published
1989
Full Text
View/download PDF

42. Liver transplantation is it possible in HIV/HCV co-infected patients?

Author

Vittecoq, D., Teicher, E., Merad, M., Vallée, J. Duclos, Dussaix, E., and Samuel, D.

Subjects
*HIV infections, *TRANSPLANTATION of organs, tissues, etc., *DISEASES
Abstract

The prognosis of HIV infection has been modified by antiretroviral therapy. However, the morbidity and the mortality of HCV co-infection increase and may be a major problem of health service. Up to now co-infected patients are excluded of transplantation due to complexity, the ethical aspects, the immunodeficiency and the co-infection. This study tries to estimate the feasibility in this population. Between December 1999 and March 2002, seven patients were transplanted. The average of CD4 was 332/ml; the viral load was <50 copies/ml. Before transplantation, no patient had experienced opportunist infection and all patients received antiretroviral therapy adapted to their history. The average follow-up is of 14 months: one patient died 3 months after transplantation, the other one presented a candida in oesophagus, the average of CD4 was 280/ml, and viral load was <50 copies/ml in five patients. A relapse of HVC was observed in all patients. Interferon/rivabirine therapy was proposed for four patients. Every patient received tacrolimus and corticoids. HAART were modified four times for toxicity and one time for virological failure. We observed two cases of transient renal insufficiency, two cases of diabetes, two cases of pancreatitis, and abnormalities of the respiratory mitochondrial chain in four patients. Finally, liver transplantation in HIV–HCV co-infected patients seems to be feasible when strict criteria of selection are taken into account. This still experimental strategy requires a multidisciplinary partnership. [Copyright &y& Elsevier]

Published
2003
Full Text
View/download PDF

44. Neutropenia due to Beta lactamine antibodies.

Author

Rouveix, B., Lassoued, K., Vittecoq, D., and Regnier, B.

Subjects
NEUTROPENIA, BETA lactam antibiotics, PATIENTS
Abstract

Examines the patient with neutropenia after beta lactamines treatment. Symptoms of the disease; Importance of clinical and serological findings for the investigation; Pathogenesis of neutropenia.

Published
1983
Full Text
View/download PDF

47. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010

Author

Rouges François, Gervais Anne, Lacombe Karine, Morlat Philippe, Barange Karl, Rosenthal Eric, Bonnard Philippe, Neau Didier, Poizot-Martin Isabelle, Valantin Marc-Antoine, Delaune Jean, Pambrun Elodie, Gillet Stéphanie, Merchadou Laurence, Mora Marion, Winnock Maria, Carrieri Patrizia, Salmon Dominique, Loko Marc-Arthur, See Alain, Lascoux-Combe Caroline, Vittecoq Daniel, Goujard Cécile, Duvivier Claudine, Spire Bruno, Izopet Jacques, Sogni Philippe, Serfaty Lawrence, Benhamou Yves, Bani-Sadr Firouzé, and Dabis François

Subjects
Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background In France, it is estimated that 24% of HIV-infected patients are also infected with HCV. Longitudinal studies addressing clinical and public health questions related to HIV-HCV co-infection (HIV-HCV clinical progression and its determinants including genetic dimension, patients' experience with these two diseases and their treatments) are limited. The ANRS CO 13 HEPAVIH cohort was set up to explore these critical questions. To describe the cohort aims and organization, monitoring and data collection procedures, baseline characteristics, as well as follow-up findings to date. Methods Inclusion criteria in the cohort were: age > 18 years, HIV-1 infection, chronic hepatitis C virus (HCV) infection or sustained response to HCV treatment. A standardized medical questionnaire collecting socio-demographic, clinical, biological, therapeutic, histological, ultrasound and endoscopic data is administered at enrolment, then every six months for cirrhotic patients or yearly for non-cirrhotic patients. Also, a self-administered questionnaire documenting socio-behavioral data and adherence to HIV and/or HCV treatments is administered at enrolment and yearly thereafter. Results A total of 1,175 patients were included from January 2006 to December 2008. Their median age at enrolment was 45 years and 70.2% were male. The median CD4 cell count was 442 (IQR: 304-633) cells/μl and HIV RNA plasma viral load was undetectable in 68.8%. Most participants (71.6%) were on HAART. Among the 1,048 HIV-HCV chronically co-infected patients, HCV genotype 1 was predominant (56%) and cirrhosis was present in 25%. As of January, 2010, after a median follow-up of 16.7 months (IQR: 11.3-25.3), 13 new cases of decompensated cirrhosis, nine hepatocellular carcinomas and 20 HCV-related deaths were reported, resulting in a cumulative HCV-related severe event rate of 1.9/100 person-years (95% CI: 1.3-2.5). The rate of HCV-related severe events was higher in cirrhotic patients and those with a low CD4 cells count, but did not differ according to sex, age, alcohol consumption, CDC clinical stage or HCV status. Conclusion The ANRS CO 13 HEPAVIH is a nation-wide cohort using a large network of HIV treatment, infectious diseases and internal medicine clinics in France, and thus is highly representative of the French population living with these two viruses and in care.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results